Personalis, Inc. (NASDAQ:PSNL) Receives Consensus Rating of "Buy" from Analysts

Shares of Personalis, Inc. (NASDAQ:PSNL - Get Free Report) have received an average rating of "Buy" from the six research firms that are covering the company, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $7.67.

Several research analysts have weighed in on the company. HC Wainwright boosted their price target on Personalis from $8.00 to $9.00 and gave the stock a "buy" rating in a research report on Wednesday, May 7th. Needham & Company LLC reissued a "buy" rating and issued a $7.00 target price on shares of Personalis in a research note on Thursday, April 10th. Craig Hallum assumed coverage on shares of Personalis in a report on Monday, March 17th. They set a "buy" rating and a $8.00 target price on the stock. Finally, Guggenheim initiated coverage on shares of Personalis in a research note on Thursday, May 15th. They issued a "buy" rating and a $6.00 price target for the company.

Institutional Investors Weigh In On Personalis

Several hedge funds have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP increased its holdings in shares of Personalis by 144.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 410,083 shares of the company's stock valued at $2,372,000 after purchasing an additional 242,141 shares during the last quarter. Two Sigma Advisers LP grew its stake in Personalis by 25.6% in the 4th quarter. Two Sigma Advisers LP now owns 34,300 shares of the company's stock valued at $198,000 after buying an additional 7,000 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in Personalis by 53,126.7% in the 4th quarter. BNP Paribas Financial Markets now owns 71,856 shares of the company's stock valued at $415,000 after acquiring an additional 71,721 shares during the period. Barclays PLC lifted its position in Personalis by 67.1% during the fourth quarter. Barclays PLC now owns 109,368 shares of the company's stock worth $632,000 after acquiring an additional 43,900 shares during the last quarter. Finally, Jane Street Group LLC lifted its position in Personalis by 144.3% during the fourth quarter. Jane Street Group LLC now owns 401,314 shares of the company's stock worth $2,320,000 after acquiring an additional 237,033 shares during the last quarter. Institutional investors and hedge funds own 61.91% of the company's stock.

Personalis Stock Performance

Personalis stock traded up $0.05 during mid-day trading on Friday, reaching $7.56. The company's stock had a trading volume of 1,039,371 shares, compared to its average volume of 1,143,323. Personalis has a 12 month low of $1.41 and a 12 month high of $7.79. The business's 50 day simple moving average is $5.36 and its 200 day simple moving average is $4.85. The company has a market capitalization of $667.26 million, a price-to-earnings ratio of -5.86 and a beta of 1.95.

Personalis (NASDAQ:PSNL - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.05. The company had revenue of $20.61 million during the quarter, compared to the consensus estimate of $17.41 million. Personalis had a negative net margin of 98.10% and a negative return on equity of 48.78%. As a group, sell-side analysts expect that Personalis will post -1.4 EPS for the current year.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.